Influence of renal replacement therapy on pharmacokinetics in critically ill patients

Best Practice and Research: Clinical Anaesthesiology

Volumn 18, Issue 1, 2004, Pages 175-187

  Bugge, Jan Frederik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute renal failure; Dialysis; Drug dosing; Haemodiafiltration; Haemofiltration; Intensive care unit; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA 2 MICROGLOBULIN; CEFTAZIDIME; CEFTRIAXONE; CILASTATIN; CIPROFLOXACIN; DIALYSIS FLUID; FLUCONAZOLE; HEPARIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; VANCOMYCIN; DRUG;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; CANDIDIASIS; CRITICAL ILLNESS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; HALF LIFE TIME; HEMODIALYSIS; HEMOFILTRATION; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OTOTOXICITY; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; ACUTE KIDNEY FAILURE; ALGORITHM; METABOLISM; PHARMACOKINETICS; RENAL REPLACEMENT THERAPY;

ALGORITHMS; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; HUMANS; KIDNEY FAILURE, ACUTE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RENAL REPLACEMENT THERAPY;

EID: 2142706636     PISSN: 15216896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpa.2003.09.002     Document Type: Review

References (75)

1. Levy G. Pharmacokinetics in renal disease American Journal of Medicine 62 1977 461-463
2. Suh B. Craig W.A. England A.C. Elliott R.L. Effect of free fatty acids on protein binding of antimicrobial agents Journal of Infectious Diseases 143 1981 609-610
3. Gulyassy P.E. Depner T.A. Impaired binding of drugs and endogenous ligands in renal disease American Journal of Kidney Diseases 2 1983 578-601
4. McNamara P.J. Lalka D. Gibaldi M. Endogenous accumulation products and serum protein binding in uremia Journal of Laboratory and Clinical Medicine 98 1981 730-740
5. Driscoll D.F. McMahon M. Blackburn G.L. Bistrain B.R. Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations Critical Care Medicine 16 1988 1248-1249
6. Gosling P. Sanghera K. Dickson G. Generalized vascular permeability and pulmonary function in patients following serious trauma Journal of Trauma 36 1994 477-481
7. Kroh U.F. Drug administration in critically ill patients with acute renal failure New Horizons 3 1995 748-759
8. Bohler J. Donauer J. Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage Kidney International 56 supplement 72 1999 S24-S28
9. Kroh U.F. Holl T.J. Steinhausser W. Management of drug dosing in continuous renal replacement therapy Seminars in Dialysis 9 1996 161-165
10. Jeffrey R.F. Khan A.A. Prabhu P. et al. A comparison of molecular clearance rates during continuous hemofiltration and haemodialysis with a novel volumetric continuous renal replacement system Artificial Organs 18 1994 425-428
11. Rumpf K.W. Rieger J. Ansorg R. et al. Binding of antibiotics by dialysis membranes and its clinical relevance Proceedings of the European Dialysis and Transplant Association 14 1977 677-688
12. Kronofol N.O. Lau A.H. Barakat M.M. Aminoglycoside binding to polyacrylonitrile hemofilter during continuous hemofiltration Transactions of the American Society of Artficial Internal Organs 33 1987 300-303
13. Oborne C.A. Buckton G. Barker N. The interaction of albumine and drugs with two hemofiltration membranes Journal of Clinical Pharmacology and Therapeutics 19 1994 119-125
14. Joy M.S. Matzke G.R. Armstrong D.K. et al. A primer on continuous renal replacement therapy for critically ill patients Annals of Pharmacotherapy 32 1998 362-375
15. Brunet S. Leblanc M. Geadah D. et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates American Journal of Kidney Diseases 34 1999 486-492
16. Kaplan A.A. Continuous arteriovenous hemofiltration and related therapies Winchester J. Replacement of Renal Function by Dialysis 1996 392-400 Kluwer Academic Dordrecht
17. Clark W.R. Ronco C. CRRT efficiency and efficacy in relation to solute size Kidney International 56 supplement 72 1999 S3-S7
18. Golper T.A. Marx M.A. Drug dosing adjustments during continuous renal replacement therapies Kidney International 53 supplement 66 1998 S165-S168
19. Vos M.C. Vincent H.H. Continuous arteriovenous hemodiafiltration: Predicting the clearance of drugs Contributions to Nephrology 93 1991 143-145
20. Vincent H.H. Vos M.C. Akcahuseyin E. et al. Drug clearance by continuous haemodiafiltration (CAVHD). Analysis of sieving coefficients and mass transfer coefficients of diffusion Blood Purification 11 1993 99-107
21. Joos B. Scmidli M. Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous hemofiltration Nephrology Dialysis Transplantation 11 1996 1582-1585
22. Aronoff G.R. Berns J.S. Brier M.E. et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults 1999 American College of Physicians Philadelphia
23. Lipman J. Crewe-Brown H.H. Saunders G.L. Gaes A.G. Subtleties of antibiotic dosing-do doses and intervals make a difference in the critically ill? South African Journal of Surgery 34 1996 160-162
24. Fry D.E. The importance of antibiotic pharmacokinetics in critical illness American Journal of Surgery 172 supplement 6A 1996 20S-25S
25. Roosendaal R. Bakker-Woudenberg I.A. van den Berghe-van Raffe M. et al Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicaemia in leukopenic rats European Journal of Clinical Microbiology and Infectious Diseases 8 1989 878-887
26. Bakker-Woudenberg I.A. Roosendaal R. Impact of dosage schedule of antibiotics on the treatment of serious infections Intensive Care Medicine 16 supplement 3 1990 S229-S234
27. Moore R.D. Lietman R.S. Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration Journal of Infectious Diseases 155 1987 93-99
28. Vogelman B. Gudmundsson S. Legett J. et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model Journal of Infectious Diseases 158 1988 831-847
29. Marik P.E. Havlik I. Monteagudo F.S. Lipman J. The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens Journal of Antimicrobial Chemotherapy 27 supplement C 1991 81-89
30. van der Auwera P. Meunier F. Ibrahim S. et al Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection Antimicrobial Agents and Chemotherapy 35 1991 640-647
31. Prins J.M. Buller H.R. Kuijper E.J. et al. Once versus thrice daily gentamicin in patients with serious infections Lancet 341 1993 335-339
32. Tran Ba Huy P. Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features Acta Otolaryngologica 105 1988 511-515
33. Zhanel G.G. Ariano R.E. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity? Renal Failure 14 1992 1-9
34. Nicolau D.P. Freeman C.D. Belliveau P.P. et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients Antimicrobial Agents and Chemotherapy 39 1995 650-655
35. Mouton J.W. Touzw D.J. Horrevorts A.M. Vinks A.A. Comparative pharmacokinetics of the carbapenems: clinical implications Clinical Pharmacokinetics 39 2000 185-201
36. Mouton J.W. den Hollander J.G. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model Antimicrobial Agents and Chemotherapy 38 1994 931-936
37. Turnidge J.D. The pharmacodynamics of beta-lactams Clinical Infectious Diseases 27 1998 10-22
38. Fantin B. Farinotti R. Thabaut A. Carbon C. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomanas aeruginosa Journal of Antimicrobial Chemotherapy 33 1994 563-569
39. Benko A.S. Capelletty D.M. Kruse J.A. Rybak M.J. Continuous infusion of versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections Antimicrobial Agents and Chemotherapy 40 1996 691-695
40. Mouton J.W. Vinks A.A. Punt N.C. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion Antimicrobial Agents and Chemotherapy 41 1997 733-738
41. MacGowan A.P. Bowker K.E. Continuous infusion of beta-lactam antibiotics Clinical Pharmacokinetics 35 1998 391-402
42. Lipman J. Wallis S.C. Richard C. Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing Antimicrobial Agents and Chemotherapy 43 1999 2559-2561
43. Lipman J. Wallis S.C. Richard C.M. Fraenkl D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modeling calls for more frequent dosing Intensive Care Medicine 27 2001 363-370
44. Pinder M. Bellomo R. Lipman J. Pharmacological principles of antibiotic prescription in the critically ill Anaesthesia and Intensive Care 30 2002 134-144
45. Christensson B.A. Nilsson-Ehle M. Hutchinson M. et al. Pharmacokinetics of meropenem in subjects with various degree of renal impairment Antimicrobial Agents and Chemotherapy 36 1992 1532-1537
46. Chimata M. Nagase M. Suzuki Y. et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease Antimicrobial Agents and Chemotherapy 37 1993 229-233
47. Przechera M. Bengel D. Risler T. Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration Contributions to Nephrology 93 1991 131-134
48. Vos M.C. Vincent H.H. Yzerman E.P.F. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD) Intensive Care Medicine 18 1992 282-285
49. Mueller S.C. Majcher-Peszynska J. Hickstein H. et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous haemodialysis Antimicrobial Agents and Chemotherapy 46 2002 1557-1560
50. Campoli-Richards D.M. Monk J.P. Price A. et al. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use Drugs 35 1988 373-447
51. Bauernfeind A. Questioning dosing regimens of ciprofloxacin Journal of Antimicrobial Chemotherapy 31 1993 789-798
52. Chin N.X. Neu H.C. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria American Journal of Medicine 82 1987 58-62
53. Forrest A. Nix D.E. Ballow C.H. et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Antimicrobial Agents and Chemotherapy 37 1993 1073-1081
54. Nix D.E. Spivey J.M. Norman A. Schentag J.J. Dose-ranging pharmacokinetic study of ciprofloxacin after 200, 300 and 400 mg intravenous doses Annals of Pharmacotherapy 26 1992 8-10
55. Wallis S.C. Mullany D.V. Lipman J. et al. Pharmacokinetics of ciprofloxacin in ICU patients on continous veno-venous haemodiafiltration Intensive Care medicine 27 2001 665-672
56. Vance-Bryan K. Guay D.R. Rotschafer J.C. Clinical pharmacokinetics of ciprofloxacin Clinical Pharmacokinetics 19 1990 434-461
57. Bellmann R. Egger P. Gritsch W. et al. Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis Acta Medica Austriaca 29 2002 112-116
58. Höffken G. Lode H. Prinzing C. et al. Pharmacokinetics of ciprofloxacin after oral and parenteral administration Antimicrobial Agents and Chemotherapy 27 1985 375-379
59. Fish D.N. Chow A.T. Clinical pharmacokinetics of levofloxacin Clinical Pharmacokinetics 32 1992 101-119
60. Malone R.S. Fish D.N. Abraham E. Teitelbaum I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients Antimicrobial Agents and Chemotherapy 45 2001 2949-2954
61. Sowinski K.M. Lucksiri A. Kays M.B. et al. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer American Journal of Kidney Diseases 42 2003 342-349
62. Saunders N.J. Vancomycin administration and monitoring reappraisal Journal of Antimicrobial Chemotherapy 36 1995 279-282
63. Larsson A.J. Walker K.J. Raddatz J.K. Rotschafer J.C. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions Journal of Antimicrobal Chemotherapy 38 1996 589-597
64. Wakanabe T. Ohashi K. Matsui K. Kubata T. Comparative studies of bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus auereus Journal of Antimicrobial Chemotherapy 39 1997 471-476
65. Wysocki M. Delatour F. Faurisson F. et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study Antimicrobial Agents and Chemotherapy 45 2001 2460-2467
66. Reeves J.H. Butt W.W. A comparison of solute clearance during continuous hemofiltration, hemodiafiltration and haemodialysis using a polysulfone hemofilter Asaio Journal 41 1995 100-104
67. Hughes C.E. Bennett R.Y. Tuna I.C. Beggs W.H. Activities of fluconazole and ketoconazole against ketoconazole susceptible and resistant Candida albicans Antimicrobial Agents and Chemotherapy 32 1988 209-212
68. Rogers T.E. Galgiani J. Activity of fluconazole and ketoconazole against Candida albicans in vitro and in vivo Antimicrobial Agents and Chemotherapy 30 1986 418-422
69. Fisher M.A. Shen H.A. Haddad J. Tarry W.F. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata and Candida crusei Antimicrobial Agents and Chemotherapy 33 1989 1443-1446
70. Debruyine D. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses Clinical Pharmacokinetics 33 1997 52-77
71. Arredondo G. Martinez-Jorda R. Calvo R. et al. Protein binding of itraconazole and fluconazole in patients with chronic renal failure International Journal of Clinical Pharmacology and Therapeutics 32 1994 361-364
72. Muhl E. Martens T. Iven H. et al. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole European Journal of Clinical Pharmacology 56 2000 671-678
73. Grant S.M. Clissold S.P. Fluconazole-a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses Drugs 39 1990 877-916
74. Diaz M. Negroni R. Montero-Gei F. et al. A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host Clinical Infectious Diseases 14 supplement 1 1992 68-76
75. Graninger W. Presteril E. Schneeweiss B. et al. Treatment of Candida albicans fungemia with fluconazole Journal of Infection 26 1993 133-146